In high-risk prostate cancer patients with early biochemical recurrence or persistence after radical treatment, novel digital PET/CT systems could potentially better leverage the sensitivity of PSMA radioligands and help to identify oligometastatic patients eligible for SABR/SBRT treatments at an earlier stage of disease recurrence, when the tumor burden is lower and treatments are more effective. The gene discussed is FOLH1; the disease is prostate cancer.